These two stocks gained 30% and 80% on Friday: here’s why

By: Wajeeh Khan
Wajeeh Khan
Wajeeh is a News Reporter at Invezz covering the European, Asian and North America stock markets. Wajeeh has 5… read more.
on Aug 27, 2021
  • shares are up over 30% on better-than-expected quarterly sales.
  • Retail traders pushed NeuroMetrix shares up 80% this morning.
  • With strong financials, NeuroMetrix is much more than just a meme stock.

The stock market is usually not very exciting on the last day of the week. But some stocks still tend to stir things up a little bit. With that said, here are the top two stocks that gained big this Friday. Holdings Inc (NYSE: BILL) said late on Thursday it lost $41.9 million in Q4 or 48 cents per share. In the comparable quarter of last year, its loss was capped at $9.5 million or 13 cents per share. Adjusted for non-recurring items, the software company lost a wider-than-expected 7 cents per share.

Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.

Shares of the company, however, are more than 30% up this morning as investors focused on better-than-expected $78.3 million in revenue that represents an annualised growth of 86%. According to FactSet, experts had forecast 4 cents of per-share loss on $62 million in sales.

For fiscal Q1, now forecasts up to $104.2 million in revenue. It, however, expects to remain in loss of 20 to 21 cents per share. Following the earnings report, Keybanc, Piper Sandler, Oppenheimer, Canaccord Genuity, and BofA Securities raised their price targets today on stock.


NeuroMetrix Inc (NASDAQ: NURO) shares are up roughly 80% on Friday as retail traders pushed the trading volume to 50 million versus 8 million in the trailing 65 days.

But NeuroMetrix is more than just a meme stock. The biotech firm has strong financials, as evident by a 62.8% annualised growth in revenue in its latest reported quarter.

On top of the upbeat earnings report, NeuroMetrix has been sustaining momentum in recent weeks on the back of its Quell device for treatment of Fibromyalgia that received breakthrough designation from the U.S. FDA.

Earlier this month, the Massachusetts-based company filed a prospectus supplement with the SEC to register the offer and sale of $14 million worth of its stock.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,
75.26% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.